GRASP Inhibitors
GRASP inhibitors refer to a class of chemical compounds that target the protein-protein interactions mediated by Golgi reassembly and stacking proteins (GRASPs). GRASPs are a family of proteins that play a crucial role in maintaining the structural integrity and functionality of the Golgi apparatus, an organelle in eukaryotic cells responsible for post-translational protein modification and trafficking. The Golgi apparatus consists of a series of flattened membrane-bound sacs or cisternae, and GRASPs are essential for the proper stacking and organization of these cisternae, facilitating efficient protein sorting and secretion.
GRASP proteins, particularly GRASP65 and GRASP55, serve as molecular bridges that tether adjacent Golgi cisternae together, forming the characteristic stacked morphology of the Golgi apparatus. This stacking is vital for the proper sorting and modification of proteins as they transit through the Golgi. GRASP inhibitors are designed to disrupt these protein-protein interactions, leading to the fragmentation or unstacking of the Golgi cisternae. By interfering with GRASP-mediated tethering, these inhibitors impact the Golgi's structural integrity, impairing its function and disrupting the ordered processing and sorting of proteins. This interference can have a significant impact on various cellular processes dependent on the Golgi, including the synthesis of lipids, glycoproteins, and other complex molecules. Researchers and scientists have been exploring GRASP inhibitors as valuable tools for understanding the fundamental biology of the Golgi apparatus and its role in intracellular protein trafficking and secretion. Studying the effects of these inhibitors can provide insights into the mechanisms underlying Golgi structure and function, shedding light on important aspects of cell biology and protein transport. Additionally, these inhibitors may hold promise in future research for their potential to uncover new targets or pathways related to cellular processes influenced by the Golgi apparatus.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Binds to the ATP-binding site of BCR-ABL kinase, inhibiting its activity. Used in chronic myeloid leukemia. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases, including RAF and VEGFR, inhibiting cell proliferation and angiogenesis. Used for advanced kidney and liver cancers. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits the EGFR kinase, blocking signal transduction pathways in cancer cells. Employed in non-small cell lung cancer | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2 kinases, disrupting growth and division in cancer cells. Used in HER2-positive breast cancer therapy. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits multiple tyrosine kinases, including BCR-ABL and SRC family kinases, interfering with cancer cell signaling. Utilized in CML and ALL. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Targets EGFR kinase, reducing cell growth and division. Prescribed for non-small cell lung cancer and pancreatic cancer | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Inhibits BCR-ABL kinase, preventing the proliferation of leukemia cells. Approved for chronic myeloid leukemia therapy. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Blocks multiple kinases, including VEGFR and PDGFR, disrupting tumor angiogenesis and growth. Used for renal cell carcinoma and GIST. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Inhibits mutant BRAF kinases, disrupting downstream signaling in melanoma cells with BRAF mutations. Utilized in melanoma therapy. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits BTK kinase, disrupting B-cell signaling pathways. Used in various B-cell malignancies like CLL and mantle cell lymphoma. | ||||||